India Rejects Patent for TB Drug Combination, Opening Door to Cheaper Generics
Published
India has rejected a patent application for the BPaL drug combination, a treatment used against tuberculosis (TB). The decision could make it easier for other companies to produce lower-cost versions of the medicine. TB remains one of the most serious infectious diseases in India, so the ruling is closely watched by doctors, patients and health experts.
BPaL is a combination of three drugs: bedaquiline, pretomanid and linezolid. It is used to treat drug-resistant forms of TB, which do not respond to many standard medicines. Treatment with newer drugs like this one can be shorter and may work better for patients who have failed older treatments. However, patents usually give a single company the exclusive right to sell a medicine for a number of years, which often keeps prices high.
Because the patent application was rejected, generic manufacturers may now be able to make and sell affordable versions of the combination. Generic competition can lower prices and help public health programmes reach more patients. Supporters of the decision say it could improve access to treatment for people who cannot afford expensive medicines. Patent rights, however, are still an important part of encouraging research into new drugs, so the decision is likely to remain a topic of debate.
For patients in India, the rejection may mean that drug-resistant TB treatment becomes more affordable in the coming years. Further details about the company's options and the timing of any generic launches are still awaited.
Sources: The Indian Express
More India news
- Cheaper Batteries Make Solar and Wind the Lowest-Cost Power Source in India, Says BNEF
- Why Money Flowing Out of India Is Drawing Attention
- Qualcomm Layoffs: What Severance Will Former Employees in India Receive?
- Suriya's Cop Comedy 'Scene' Earns Rs 111 Crore in Five Days at the Box Office
- Ajay Devgn's Drishyam 3: The Conclusion Passes Rs 588 Crore Worldwide After 40 Days
- Ramayana: Part 1 Continues Strong Box Office Run with Rs 440 Crore Collection
- Government Uses Online Marketplace to Buy Farm and Allied Sector Goods
- World Bank Estimates Extreme Poverty in India at 2.6 Per Cent, Sparking Debate